Journal ArticleDOI
Albumin as a versatile platform for drug half-life extension.
TLDR
The manipulation of the albumin-FcRn interaction will facilitate the modulation of the circulatory half-life ofalbumin-enabled drugs, leading to superior pharmacokinetics tailored to the disease state and increased patient compliance.About:
This article is published in Biochimica et Biophysica Acta.The article was published on 2013-12-01. It has received 366 citations till now. The article focuses on the topics: Serum albumin.read more
Citations
More filters
Journal ArticleDOI
Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies
TL;DR: Recent advances in formulation and delivery strategies, such as the use of microsphere-based controlled-release technologies, protein modification methods that make use of polyethylene glycol and other polymers, and genetic manipulation of biopharmaceutical drugs are highlighted and discussed.
Journal ArticleDOI
The Current State of Peptide Drug Discovery: Back to the Future?
TL;DR: An emphasis is placed on describing research efforts to overcome the inherent weaknesses of peptide drugs, in particular their poor pharmacokinetic properties, and how these efforts have been critical to the discovery, design, and subsequent development of novel therapeutics.
Journal ArticleDOI
The making of bispecific antibodies
TL;DR: There is not ‘one best format’ for generating bispecific antibodies, and no single format is suitable for all, or even most of, the desired applications, but the bispespecific formats collectively serve as a valuable source of diversity that can be applied to the development of therapeutics for various indications.
Journal ArticleDOI
Albumin-based drug delivery: harnessing nature to cure disease
TL;DR: This review will give an overview of albumin-based products with focus on the natural biological properties and molecular interactions that can be harnessed for the design of a next-generation drug delivery platform.
Journal ArticleDOI
Human serum albumin, systemic inflammation, and cirrhosis
TL;DR: Human serum albumin (HSA) is one of the most frequent treatments in patients with decompensated cirrhosis, and its ability to bind lipopolysaccharide and other bacterial products, reactive oxygen species, nitric oxide and other nitrogen reactive species, and prostaglandins is an outstanding feature.
References
More filters
Journal ArticleDOI
FcRn: the neonatal Fc receptor comes of age
TL;DR: The neonatal Fc receptor for IgG (FcRn) has been well characterized in the transfer of passive humoral immunity from a mother to her fetus and throughout life, FcRm protects IgG from degradation, thereby explaining the long half-life of this class of antibody in the serum.
Journal ArticleDOI
Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles.
TL;DR: This review gives an account of the different drug delivery systems which make use of albumin as a drug carrier with a focus on those systems that have reached an advanced stage of preclinical evaluation or that have entered clinical trials.
Journal ArticleDOI
Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites
TL;DR: The crystal structure of HSA complexed with five molecules of myristate at 2.5 Å resolution is determined and it is shown that fatty acid molecules bind in long, hydrophobic pockets capped by polar side chains, many of which are basic.
Journal ArticleDOI
Properties of the Glomerular Barrier and Mechanisms of Proteinuria
TL;DR: The cellular components are the key players in restricting solute transport, while the GBM is responsible for most of the resistance to water flow across the glomerular barrier.
Journal ArticleDOI
Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins
Mark S. Dennis,Min Zhang,Y. Gloria Meng,Miryam Kadkhodayan,Daniel Kirchhofer,Dan Combs,Lisa A. Damico +6 more
TL;DR: A series of peptides having the core sequence DICLPRWGCLW that specifically bind serum albumin from multiple species with high affinity are identified, suggesting a novel and generic method for improving the pharmacokinetic properties of rapidly cleared proteins.